Investigating the Clinical Performance of Zelenectide Pevedotin & BT5528 to Understand Class Effect Differences of Bicycle Toxin Conjugates Against Classical ADC Formats
Time: 8:30 am
day: Conference Day Two pt 1
Details:
• Laying out the emerging safety profiles of zelenectide pevedotin and BT5528, and comparing toxicity characterisation against classical ADC formats
• Delving into BT5528 clinical toxicity profile against EphA2 in contrast to ADCs against the same target
• Rationalising preclinical and clinical differences with PKPD analysis and understanding the advantages of BTCs design and performance
